Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third-Party MSCs for Liver Transplant Tolerance
NCT02260375Phase 1Unknown
- Start
- Oct 2014
- Primary completion
- Oct 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Provacel in Liver transplant rejection (2 arms). Primary endpoints: Number of adverse events at 120 months, Liver tissue mRNA level of Transferrin receptor CD71 (TFRC) and Hepcidin antimicrobial peptide (HAMP) genes at 60 months and 2 more. Status: unknown.
02
Drugs
Provacel
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT02260375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260375.